Jian Yang with Ph.D. student Chuying Ma displaying a bendable citrate-based...
Jian Yang with Ph.D. student Chuying Ma displaying a bendable citrate-based material for bone repair.

Credit: Walt Mills/Penn State

Less rejection

Citrate-based biomaterial fuels bone healing

A material based on a natural product of bones and citrus fruits, called citrate, provides the extra energy stem cells need to form new bone tissue, according to a team of Penn State bioengineers. The new understanding of the mechanism that allows citrate to aid in bone regeneration will help the researchers develop slow-release, biodegradable citrate-releasing scaffolds to act as bone-growth templates to speed up healing in the body.

“In our lab, we have been working with citrate for over a decade,” said Jian Yang, professor of biomedical engineering, Penn State. “We knew that in the human body, 90 percent of organic citrate is located in skeletal tissue. But no one had really tried to use citrate as a building block to make bone biomaterials. Our new paper tries to understand how citrate helps in bone healing and uses the understanding to guide the design of new biomimetic biomaterials for better bone repair.”

Most bone regeneration in a hospital setting is done through the autograft, taking bone from another part of the patient’s body and grafting it to the wound. This is not a sustainable method, especially in the case of large wounds or bone tissue removed during cancer treatment. Synthetic biomaterials would be a welcome replacement and many labs are working on developing them. But the current synthetic materials cause significant inflammation and the bone healing rate is slow and the healing quality is poor. The body encapsulates the implant with fibrotic tissues that keep the implant from integrating with surrounding bone. With Yang’s material, they do not see encapsulation and the chronic inflammation is minimal.

Chuying Ma, a Ph.D. student in Yang’s lab, is lead author on a paper published in the Proceedings of the National Academy of Sciences (PNAS). Ma was given the problem of uncovering the poorly known mechanism underlying the body’s use of citrate to regenerate bone. She found that the stem cell membrane has a transporter that is used to transport citrate into the cell to elevate the cellular energy level. When the bone stem cells differentiate to make new bone cells, they require more energy as support for active bone formation. The timing and dosage of citrate supply to stem cells are also critical. Yang and Ma coined the newly identified citrate effect on stem cell differentiation as “metabonegenic regulation” in the paper.

The team also identified a second factor involved in energy production, an amino acid called phosphoserine. With their new understanding of the mechanism for bone regrowth, they developed a biomaterial incorporating both citrate and phosphoserine and tested it on rat models. “Using our new material, we see the early deposition of new bone at one month,” Ma said. “This is much earlier than the biomaterials widely used in FDA-approved devices. In this study we tested two models, the femoral condyle bone and the cranial bone defects. In both animal models we see the new biomaterial is better than the commercial materials in inducing early bone formation and also promoting bone maturation.”  

Yang added, “To me, this is an important finding. Citrate is now recognized as a central linker between stem cell metabolism and differentiation. We are uncovering the mechanism whereby citrate influences stem cell activity, not only in bone, but by implication extending to other types of cells and tissues. For instance, there is a high concentration of citrate in the cerebrospinal fluid surrounding the brain. People can now use this understanding to start looking at citrate as a metabolism regulator to further regulate stem cells for other types of tissues and organs throughout the body.”

Source: Penn State Materials Research Institute

10.12.2018

Read all latest stories

Related articles

Photo

Health economics

Why certified cancer centers are worth the extra input

Quality assurance in cancer medicine has a reputation for being expensive and involving considerable outlay. For the first time, a cost-effectiveness analysis has now shown that patients treated in…

Photo

Oncology

Pancreatic cancer - current challenges and future direction

Pancreatic cancer is one of the deadliest cancers in the world, and one of the most difficult to treat. In 2020, an estimated 495,000 individuals worldwide were diagnosed with pancreatic cancer and…

Photo

Cancer 'avatars'

Predicting immunotherapy outcomes with mini tumours

Miniature tumours in the lab are able to predict whether the corresponding real-life patients will benefit from immunotherapy. “We’ve solved a major problem many scientists had been facing:…

Related products

Canon - Aquilion Exceed LB

Oncology CT

Canon - Aquilion Exceed LB

Canon Medical Systems Europe B.V.
Siemens Healthineers – Somatom go.Open Pro

Oncology CT

Siemens Healthineers – Somatom go.Open Pro

Siemens Healthineers
Siemens Healthineers – Somatom go.Sim

Oncology CT

Siemens Healthineers – Somatom go.Sim

Siemens Healthineers
Subscribe to Newsletter